Literature DB >> 29631783

Denosumab: a new treatment option for glucocorticoid-induced osteoporosis.

Elena Tsourdi1, Lorenz C Hofbauer2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29631783     DOI： 10.1016/S2213-8587(18)30097-4

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  2 in total

1.  MicroRNA-92b-5p modulates melatonin-mediated osteogenic differentiation of bone marrow mesenchymal stem cells by targeting ICAM-1.

Authors:  Yuan Li; Chao Feng; Manqi Gao; Mengyu Jin; Tianyi Liu; Ye Yuan; Gege Yan; Rui Gong; Yi Sun; Mingyu He; Yutuo Fu; Lai Zhang; Qi Huang; Fengzhi Ding; Wenya Ma; Zhenggang Bi; Chaoqian Xu; Natalia Sukhareva; Djibril Bamba; Russel Reiters; Fan Yang; Benzhi Cai; Lei Yang
Journal:  J Cell Mol Med       Date:  2019-07-14       Impact factor: 5.310

2.  Activation of dopamine receptor D1 promotes osteogenic differentiation and reduces glucocorticoid-induced bone loss by upregulating the ERK1/2 signaling pathway.

Authors:  Jie Zhu; Chengcheng Feng; Weicheng Zhang; Zhidong Wang; Mengdan Zhong; Wenkai Tang; Zhifang Wang; Haiwei Shi; Zhengyu Yin; Jiandong Shi; Yu Huang; Long Xiao; Dechun Geng; Zhirong Wang
Journal:  Mol Med       Date:  2022-02-21       Impact factor: 6.354
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.